These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 4572798

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C, Wolfram G, Zöllner N.
    Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
    [Abstract] [Full Text] [Related]

  • 9. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J, de Neuman MP, Talmasky S, Pesce R, Valero E, Martiarena JL.
    J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA, Azarnoff DL, Huffman DH, Pentikäinen P, Hurwitz A, Shoeman DW.
    Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A two-year crossover therapeutic trial with halofenate and clofibrate.
    Dujovne CA, Azarnoff DL, Pentikainen P, Manion C, Hurwitz A, Hassanein K.
    Am J Med Sci; 1976 Mar; 272(3):277-84. PubMed ID: 797258
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Implications of 4S evidence on baseline lipid levels.
    Durrington PN.
    Lancet; 1995 Jul 15; 346(8968):181. PubMed ID: 7661979
    [No Abstract] [Full Text] [Related]

  • 17. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep 15; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM.
    Kardiologiia; 2004 Sep 15; 44(3):87-93. PubMed ID: 15489838
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.